Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian Registry on acromegaly

T’Sjoen, Guy; Bex, Marie; Maiter, Dominique; Velkeniers, Brigitte; Abs, Roger

doi:10.1530/eje-07-0356

Cited by 52 publications

(57 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to published studies men had better quality of life in some studies [4,16,19], whereas others show opposite results [5,20,21]. In our study younger patients had slightly higher quality of life scores, but again, these failed to reach statistical significance.…”

Section: Resultscontrasting

confidence: 70%

“…In our study younger patients had slightly higher quality of life scores, but again, these failed to reach statistical significance. Previous studies showed that younger age was associated with better quality of life [14] and negative influence of age has been reported [5], whereas other studies have found no relationship [4,16,21,22]. In a recent Japanese study young age and previous radiotherapy were found to be associated with lower quality of life [23].…”

Section: Resultsmentioning

confidence: 93%

“…Radiotherapy has been associated with worse quality of life in previous studies [4,14,15]. Pituitary deficiency negatively affects quality of life [16]. Persistent comorbidities impair quality of life in acromegaly [17].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Quality of Life in Acromegaly and the Association with the Clinical Parameters of the Disease

Papadakis¹

2017

EMIJ

View full text Add to dashboard Cite

Background: Quality of life is currently considered a major factor in the assessment of disease outcome. Most patients with acromegaly present with skin, bone and soft tissue alterations, as well as hypertension, diabetes mellitus and other cardiovascular symptoms and all these affect patient's mood, personality, interpersonal relationships and social behavior. The aim of this study was to assess quality of life in acromegaly and the association with the clinical characteristics of the disease. Methods:This cross-sectional study included a total of 101 (45 male, 56 female) patients with acromegaly, mean age 59.51 ± 1.35 years (mean ± SEM), with a disease duration of 12.88 ± 0.96 years. All subjects completed the Acromegaly Quality of Life Questionnaire (AcroQoL). Results:Total (mean ± SEM) score was 86.15±1.37 (min22-max110), psychological parameters score was 54.98±0,95 (min 14-max 70), appearance score was 25.95±0.54 (min 7-max 35), personal relationship score was 29.37±0.52 (min7-max 35) and finally physical parameters score was 30.93±0.58 (min8-max 40). Women and older patients showed slightly worse scores. Patients with macroadenomas, those who received radiotherapy, and those with comorbidities appeared with less mean total QoL scores. Conclusion:The assessment of quality of life is a critical end point in the management of acromegaly and improvement of quality of life is a major aim in the therapeutic management of acromegaly.

show abstract

Section: Resultscontrasting

confidence: 70%

Section: Resultsmentioning

confidence: 93%

See 1 more Smart Citation

Quality of Life in Acromegaly and the Association with the Clinical Parameters of the Disease

Papadakis¹

2017

EMIJ

View full text Add to dashboard Cite

show abstract

“…Previous analyses of the German pegvisomant observational study (16,17) have already given useful insights into the 'real-life' use of pegvisomant and assisted physicians with issues such as optimising dose titration (6). Several countries have organized national registries of patients with acromegaly, which contribute to gain insights on the actual conditions of diagnosis and treatment of this rare disease (10,11,18). The French Acromegaly Registry represents one such register that could be used to compare the profile of a general population of patients with acromegaly to the subset of patients treated with pegvisomant and included into ACROSTUDY.…”

Section: Discussionmentioning

confidence: 99%

Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY

Brue

Castinetti²,

Lundgren³

et al. 2009

European Journal of Endocrinology

View full text Add to dashboard Cite

Context: Pegvisomant (Somavert, Pfizer Inc.) is the first and only available GH receptor antagonist. ACROSTUDY is an international surveillance study that offers inclusion in a web-based registry to all patients with acromegaly treated with pegvisomant; it aims at monitoring long-term safety and efficacy of this compound. Results: Of all patients, 80% were reported to have had surgery and 33% to have received radiation therapy. Of the 792 patients, 14% had received no prior medical treatment before pegvisomant start, 65.9% had received somatostatin analogues and 18.6% dopamine agonists. Interestingly, 66.7% had received only pegvisomant at study start, while it was taken in association with dopamine agonists in 5.7%, with somatostatin analogues in 23.4% and with both types of agents in 3.8%. Mean IGF1 at baseline was 522 ng/ml. Conclusion: Analysis of the baseline features of these patients treated with pegvisomant and reported in the ACROSTUDY database underscores the severity of the disease in this subset of the population of patients with acromegaly previously unresponsive to several medical, surgical or radiation treatment approaches.

show abstract

“…Correlations between well-known complications and levels of GH and IGF1 are still a matter of debate. Along with increased risk for mortality and morbidity in acromegaly patients, non-biochemical parameters do not necessarily correlate with biochemical activity of acromegaly [34,35]. Correlations between levels of GH and IGF1 and motility parameters were not reported in previous acromegaly studies.…”

Section: Discussionmentioning

confidence: 99%

Akromegalia może wiązać się z zaburzeniami rozkurczu dolnego zwieracza przełyku (LES)

İlhan

Danalıoğlu

Turgut

et al. 2015

Endokrynologia Polska

View full text Add to dashboard Cite

Introduction: Although prolonged small intestine and colonic transit time has been demonstrated in acromegaly patients, the influence of acromegaly on oesophagus motility and the pathological mechanisms involved are still not clarified. We aimed to investigate manometric measurements to ascertain whether oesophagus motility is affected in active acromegaly patients. Material and methods:The study was performed in an institutional referral centre at a tertiary care hospital. Twenty-three acromegaly patients (mean age 43.2 ± 13.2 years) and 25 sex-and age-matched healthy control subjects (mean age 48.6 ± 7.9 years) were recruited to a case-control study. Oesophageal manometry was performed using MMS (Medical Measurement Systems, Netherlands) Solar GI -Air Charged Intelligent Gastrointestinal Conventional Manometry. Results: In manometric measurements the lower oesophageal sphincter pressure was 18 ± 7 mmHg in acromegaly patients and 15.6 ± 4.4 mm Hg in controls, and there was no significant difference (p = 0.17). The percentage of relaxation was 64.8% and 81.8%, respectively, and it was significantly lower in acromegaly patients than in controls (p < 0.001). Additionally, the duration of relaxation was found to be 4 ± 1.9 seconds and 5 ± 1.7 seconds in patients and controls, respectively (p = 0.049). Conclusions:Our study has demonstrated a significant reduction in the percentage and duration of lower oesophageal sphincter relaxation in oesophagus motility even in acromegaly patients without any gastrointestinal symptoms. Further clinical and pathophysiological studies are required to clarify the underlying mechanisms of gastrointestinal motility disorders in acromegaly. (Endokrynol Pol 2015; 66 (4): 308-312)

show abstract

Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian Registry on acromegaly

Cited by 52 publications

References 25 publications

Quality of Life in Acromegaly and the Association with the Clinical Parameters of the Disease

Quality of Life in Acromegaly and the Association with the Clinical Parameters of the Disease

Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY

Akromegalia może wiązać się z zaburzeniami rozkurczu dolnego zwieracza przełyku (LES)

Contact Info

Product

Resources

About